August 10, 2016 / 10:52 AM / a year ago

BRIEF-Oncolytics reports additional data from phase II study of Reolysin

Aug 10 (Reuters) - Oncolytics Biotech Inc

* Oncolytics Biotech Inc. reports additional data from randomized phase II study of Reolysin in non-small cell lung cancer

* Study demonstrates statistically significant improvement in progression free survival in female patients with Adenocarcinoma

* Based on findings from IND 211, intends to include preselection of patients using genetic screening in future study protocols Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below